[Pulmonary lymphangiomyomatosis. Long-term benefit of anti-estrogen treatments remains uncertain].
Lymphangiomyomatosis is a rare disease which affects young women of childbearing age. Ten women with pulmonary lymphangiomyomatosis were treated with antiestrogen therapy from 3 to 9 years (mean time of treatment: 5.3 years). Efficacy of treatment was evaluated by clinical, radiological, pulmonary function testing response as well as the overall long-term outcome. Four patients died of respiratory failure after 3, 5, 5 and 9 years of treatment. Of the 6 patients remaining alive, respiratory function deteriorated in 4 cases after a transient period of mild improvement lasting 3 years in 2 cases. Two patients appeared stable after 3 and 7 years of treatment. Without a control group, although a longer time of survival along these last years, it seems difficult to impute this benefit to the sole antiestrogen treatment and the overall long term prognosis of the disease remains really uncertain.
Lacronique
J
J
Service de Pneumologie, Hôpital Cochin, Paris.
Urban
T
T
Kuttenn
F
F
Marsac
J
J
Gompel
A
A
D000328:Adult; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D018192:Lymphangioleiomyomatosis / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D008875:Middle Aged; D010052:Ovariectomy; D013997:Time Factors
D004965:Estrogen Antagonists